The diabetic foot ulcer treatment market has seen considerable growth due to a variety of factors.
• The market for treating diabetic foot ulcers has seen strong growth in the last several years. It is predicted to increase from $7.43 billion in 2024 to $8.02 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.9%. Factors contributing to its growth during the historic period include the rise in diabetes cases, enhanced awareness and early diagnosis, improved patient education, governmental initiatives and healthcare policies, a multidisciplinary approach to treatment, as well as wound care guidelines and protocols.
The Diabetic Foot Ulcer Treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for treating diabetic foot ulcers is predicted to experience a significant expansion in the coming years. It is set to heighten to $11.25 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%.
This upswing in the projected years can be ascribed to factors such as amplified campaigns for diabetes awareness, personalized treatment methodologies, patient-focused care models, and initiatives based on healthcare values, as well as ongoing medical education. Some noteworthy trends for the forecast period comprise of progress in technology regarding wound care products, multidisciplinary care units, focus on offloading strategies, addition of bioactive dressings, budget-friendly and outpatient treatment choices, and a rising trend in the use of hyperbaric oxygen therapy.
The surge in diabetes cases is projected to drive the expansion of the market for diabetic foot ulcer treatment. Characterized by high blood sugar levels, diabetes is a long-term metabolic disorder that gradually wreaks considerable damage to vital organs such as the heart, blood vessels, eyes, kidneys, and nerves. As the primary cause of foot ulcers, diabetes boosts the need for treatments specific to diabetic foot ulcers. For instance, the Centers for Disease Control and Prevention, a national public health agency in the US, stated in 2022 that approximately 37.3 million people, or 11.3% of the American population, are struggling with diabetes. Consequently, the growth of the diabetic foot ulcer treatment market is fueled by the rising number of diabetes sufferers.
The diabetic foot ulcer treatment market covered in this report is segmented –
1) By Treatment: Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications, Other Treatments
2) By Ulcer Type: Neuropathic Ulcers, Ischemic Ulcers, Neuro-Ischemic Ulcers
3) By Grade: Grade 1, Grade 2, Grade 3, Grade 4, Grade 5
4) By End-User: Hospital, Ambulatory Surgery Centre, Other End-Users
Subsegments:
1) By Wound Care Dressings: Hydrogels, Foam Dressings, Alginates, Antimicrobial Dressings
2) By Biologics: Growth Factors, Skin Substitutes, Cellular Therapies
3) By Therapy Devices: Negative Pressure Wound Therapy (NPWT) Devices, Electrical Stimulation Devices, Hyperbaric Oxygen Therapy Devices
4) By Antibiotic Medications: Topical Antibiotics, Systemic Antibiotics
5) By Other Treatments: Debridement Procedures, Compression Therapy, Offloading Devices
Technological innovation has emerged as a significant trend in the market for diabetic foot ulcer treatments. The primary players in the market are placing emphasis on groundbreaking technologies such as AI technology based in the cloud for the identification of diabetic foot ulcers. For example, the Indian multinational pharmaceutical corporation, Ipca Laboratories, introduced a unique topical gel called Diulcus to combat diabetic foot ulcer (DFU) in India in August 2024. Diulcus 15 mg gel has been set at a price of Rs 1365 per pack by Ipca, and it is anticipated to soon be distributed throughout its network of 4000 distributors across India.
Major companies operating in the diabetic foot ulcer treatment market include:
• Coloplast A/S
• Medtronic PLC
• Molnlycke Health Care AB
• B. Braun Melsungen AG
• Medline Industries Inc.
• ConvaTec Inc.
• Acelity L.P. Inc.
• 3M Healthcare
• Smith & Nephew PLC
• Organogenesis Inc.
• BSN Medical GMBH
• Integra LifeSciences Corporation
• Derma Sciences Inc.
• Advancis Medical
• Tissue Regenix Group PLC
• MiMedx Group Inc.
• Kerecis
• Human Regenerative Technologies LLC
• AOTI Inc.
• Lohmann & Rauscher International GmbH & Co. KG
• Urgo Medical
• L&R USA Inc.
• Misonix Inc.
• Bioventus
• Cellumed Co. Ltd.
North America was the largest region in the diabetic foot ulcer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic foot ulcer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.